Moderna says research has demonstrated safety profile of Spikevax

Moderna (MRNA) issued the following statement on the safety of Spikevax: “The safety of Spikevax is rigorously monitored by Moderna, the U.S. FDA, and regulators in more than 90 countries. Multiple, overlapping safety monitoring systems are in place that work to detect and evaluate any new or evolving safety considerations. With more than one billion doses distributed globally, these systems – including in national health systems across Europe, the United Kingdom, Canada, Australia, and the U.S. – have not reported any new or undisclosed safety concerns in children or in pregnant women. Moderna is not aware of any deaths in the last year or pertinent new information from prior years. Published, peer-reviewed research by multiple governments, independent investigators and by Moderna has demonstrated the safety profile of Spikevax. COVID-19 vaccination has not been shown to cause miscarriage, stillbirth, preterm birth, or birth defects. Importantly, vaccination protects pregnant individuals from severe COVID-19, which is linked to higher rates of maternal complications and mortality. Similarly, global pediatric surveillance data continues to demonstrate the safety profile of Spikevax in pediatric populations.”